Trial Profile
A Phase 1, Multinational Study of MCLA-117 in Acute Myelogenous Leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 May 2023
Price :
$35
*
At a glance
- Drugs Tepoditamab (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; First in man
- Sponsors Merus
- 06 May 2021 Planned End Date changed from 1 Dec 2018 to 1 Jul 2021.
- 06 May 2021 Planned primary completion date changed from 1 Dec 2018 to 1 Jul 2021.
- 06 May 2021 Status changed from recruiting to active, no longer recruiting.